Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside

References

• Nakagawara A, Ohira M. Comprehensive genomics linking between neural development and cancer: neuroblastoma as a model. Cancer Lett. 2004;204:213-24. doi:10.1016/S0304-3835(03)00457-9. PMID:15013220
   PubMed Web of Science ®Google Scholar
• Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI, Look AT, Rowe ST, Nash MB, Holbrook T, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience–a pediatric oncology group study. J Clin Oncol. 1998;16:2007-17. doi:10.1200/JCO.1998.16.6.2007. PMID:9626197
   PubMed Web of Science ®Google Scholar
• Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, Modak S. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30:3264-70. doi:10.1200/JCO.2011.41.3807. PMID:22869886
   PubMed Web of Science ®Google Scholar
• Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14:472-80. doi:10.1016/S1470-2045(13)70095-0. PMID:23598171
   PubMed Web of Science ®Google Scholar
• Flandin I, Hartmann O, Michon J, Pinkerton R, Coze C, Stephan JL, Fourquet B, Valteau-Couanet D, Bergeron C, Philip T, et al. Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology. Int J Radiat Oncol Biol Phys. 2006;64:1424-31. doi:10.1016/j.ijrobp.2005.10.020. PMID:16427213
   PubMed Web of Science ®Google Scholar
• Martin A, Schneiderman J, Helenowski IB, Morgan E, Dilley K, Danner-Koptik K, Hatahet M, Shimada H, Cohn SL, Kletzel M, et al. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. Pediatr Blood Cancer. 2014;61:1350-6. doi:10.1002/pbc.25033. PMID:24634399
   PubMed Web of Science ®Google Scholar
• Trahair TN, Vowels MR, Johnston K, Cohn RJ, Russell SJ, Neville KA, Carroll S, Marshall GM. Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplant. 2007;40:741-6. doi:10.1038/sj.bmt.1705809. PMID:17724446
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324-34. doi:10.1056/NEJMoa0911123. PMID:20879881
   PubMed Web of Science ®Google Scholar
• Yuki N, Yamada M, Tagawa Y, Takahashi H, Handa S. Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy. J Neurol Sci. 1997;149:127-30. doi:10.1016/S0022-510X(97)05390-2. PMID:9171318
   PubMed Web of Science ®Google Scholar
• Alvarez-Rueda N, Desselle A, Cochonneau D, Chaumette T, Clemenceau B, Leprieur S, Bougras G, Supiot S, Mussini JM, Barbet J, et al. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity. PLoS One. 2011;6:e25220. doi:10.1371/journal.pone.0025220. PMID:21966461
   PubMed Web of Science ®Google Scholar
• Terme M, Dorvillius M, Cochonneau D, Chaumette T, Xiao W, Diccianni MB, Barbet J, Yu AL, Paris F, Sorkin LS, et al. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. PLoS One. 2014;9:e87210. doi:10.1371/journal.pone.0087210. PMID:24520328
   PubMed Web of Science ®Google Scholar
• Cochonneau D, Terme M, Michaud A, Dorvillius M, Gautier N, Frikeche J, Alvarez-Rueda N, Bougras G, Aubry J, Paris F, et al. Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo. Cancer Lett. 2013;333:194-204. doi:10.1016/j.canlet.2013.01.032. PMID:23370223
   PubMed Web of Science ®Google Scholar
• Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol. 1994;12:539-43. doi:10.1200/JCO.1994.12.3.539. PMID:8120551
   PubMed Web of Science ®Google Scholar
• Hettmer S, McCarter R, Ladisch S, Kaucic K. Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid. Br J Cancer. 2004;91:389-97. PMID:15187999
   PubMed Web of Science ®Google Scholar
• Rebhan M, Vacun G, Bayreuther K, Rosner H. Altered ganglioside expression by SH-SY5Y cells upon retinoic acid-induced neuronal differentiation. Neuroreport. 1994;5:941-4. doi:10.1097/00001756-199404000-00022. PMID:8061301
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55. doi:10.1016/0065-2571(84)90007-4. PMID:6382953
   PubMedGoogle Scholar
• Roque-Navarro L, Chakrabandhu K, de Leon J, Rodriguez S, Toledo C, Carr A, de Acosta CM, Hueber AO, Perez R. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther. 2008;7:2033-41. doi:10.1158/1535-7163.MCT-08-0222. PMID:18645013
   PubMed Web of Science ®Google Scholar
• Fernandez-Marrero Y, Roque-Navarro L, Hernandez T, Dorvignit D, Molina-Perez M, Gonzalez A, Sosa K, Lopez-Requena A, Perez R, de Acosta CM. A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates. Immunobiology. 2011;216:1239-47. doi:10.1016/j.imbio.2011.07.004. PMID:21802167
   PubMed Web of Science ®Google Scholar
• Kane AB. Redefining cell death. Am J Pathol. 1995;146:1-2. PMID:7856718
   PubMed Web of Science ®Google Scholar
• Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 1995;146:3-15. PMID:7856735
   PubMed Web of Science ®Google Scholar
• Trump BF, Berezesky IK, Chang SH, Phelps PC. The pathways of cell death: oncosis, apoptosis, and necrosis. Toxicol Pathol. 1997;25:82-8. doi:10.1177/019262339702500116. PMID:9061857
   PubMed Web of Science ®Google Scholar
• Norris RE, Adamson PC, Nguyen VT, Fox E. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. Pediatr Blood Cancer. 2014;61:145-50. doi:10.1002/pbc.24697. PMID:24038812
   PubMed Web of Science ®Google Scholar
• Kim ES, Soffer SZ, Huang J, McCrudden KW, Yokoi A, Manley CA, Middlesworth W, Kandel JJ, Yamashiro DJ. Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. J Pediatr Surg. 2002;37:518-22. doi:10.1053/jpsu.2002.30855. PMID:11877680
   PubMed Web of Science ®Google Scholar
• Iyer R, Evans AE, Qi X, Ho R, Minturn JE, Zhao H, Balamuth N, Maris JM, Brodeur GM. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin Cancer Res. 2010;16:1478-85. doi:10.1158/1078-0432.CCR-09-1531. PMID:20179224
   PubMed Web of Science ®Google Scholar
• Ullman-Cullere MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci. 1999;49:319-23. PMID:10403450
   PubMedGoogle Scholar
• Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. J Pediatr Hematol Oncol. 2013;35:337-47. doi:10.1097/MPH.0b013e318299d637. PMID:23703550
   PubMed Web of Science ®Google Scholar
• Kowalczyk A, Gil M, Horwacik I, Odrowaz Z, Kozbor D, Rokita H. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Cancer Lett. 2009;281:171-82. doi:10.1016/j.canlet.2009.02.040. PMID:19339105
   PubMed Web of Science ®Google Scholar
• Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda R, Furukawa K. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 2001;61:4244-52. PMID:11358851
   PubMed Web of Science ®Google Scholar
• Sjoberg ER, Manzi AE, Khoo KH, Dell A, Varki A. Structural and immunological characterization of O-acetylated GD2. Evidence that GD2 is an acceptor for ganglioside O-acetyltransferase in human melanoma cells. J Biol Chem. 1992;267:16200-11. PMID:1644805
   PubMed Web of Science ®Google Scholar
• Ye JN, Cheung NK. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies. Int J Cancer. 1992;50:197-201. doi:10.1002/ijc.2910500207. PMID:1730513
   PubMed Web of Science ®Google Scholar
• Tsao CY, Sabbatino F, Cheung NV, Hsu JC, Villani V, Wang X, Ferrone S. Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells. Oncoimmunology. 2015;4:e1023975. doi:10.1080/2162402X.2015.1023975. PMID:26405581
   PubMed Web of Science ®Google Scholar
• Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer. 2001;92:2699-708. doi:10.1002/1097-0142(20011115)92:10%3c2699::AID-CNCR1624%3e3.0.CO;2-A. PMID:11745206
   PubMed Web of Science ®Google Scholar
• Weerasinghe P, Hallock S, Tang SC, Liepins A. Sanguinarine induces bimodal cell death in K562 but not in high Bcl-2-expressing JM1 cells. Pathol Res Pract. 2001;197:717-26. doi:10.1078/0344-0338-00150. PMID:11770015
   PubMed Web of Science ®Google Scholar
• Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst. 1997;89:1586-94. doi:10.1093/jnci/89.21.1586. PMID:9362156
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, Watanabe T, Akashi K, Shultz LD, Harada M. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005;106:1565-73. doi:10.1182/blood-2005-02-0516. PMID:15920010
   PubMed Web of Science ®Google Scholar
• Wei J, DeAngulo G, Sun W, Hussain SF, Vasquez H, Jordan J, Weinberg J, Wolff J, Koshkina N, Heimberger AB. Topotecan enhances immune clearance of gliomas. Cancer Immunol Immunother. 2009;58:259-70. doi:10.1007/s00262-008-0550-1. PMID:18594817
   PubMed Web of Science ®Google Scholar
• Trojandt S, Knies D, Pektor S, Ritz S, Mailander V, Grabbe S, Reske-Kunz AB, Bros M. The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells. Cancer Immunol Immunother. 2013;62:1315-26. doi:10.1007/s00262-013-1431-9. PMID:23666509
   PubMed Web of Science ®Google Scholar
• Kitai Y, Kawasaki T, Sueyoshi T, Kobiyama K, Ishii KJ, Zou J, Akira S, Matsuda T, Kawai T. DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity. J Immunol. 2017;198:1649-59. doi:10.4049/jimmunol.1601694. PMID:28069806
   PubMed Web of Science ®Google Scholar
• Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, Simon W, Murdter TE, Aulitzky WE. Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer. 2008;8:364. doi:10.1186/1471-2407-8-364. PMID:19077243
   PubMed Web of Science ®Google Scholar
• Daenen LG, Roodhart JM, van Amersfoort M, Dehnad M, Roessingh W, Ulfman LH, Derksen PW, Voest EE. Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. Cancer Res. 2011;71:6976-85. doi:10.1158/0008-5472.CAN-11-0627. PMID:21975929
   PubMed Web of Science ®Google Scholar
• Chan TS, Hsu CC, Pai VC, Liao WY, Huang SS, Tan KT, Yen CJ, Hsu SC, Chen WY, Shan YS, et al. Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. J Exp Med. 2016;213:2967-88. doi:10.1084/jem.20151665. PMID:27881732
   PubMed Web of Science ®Google Scholar
• Taschner-Mandl S, Schwarz M, Blaha J, Kauer M, Kromp F, Frank N, Rifatbegovic F, Weiss T, Ladenstein R, Hohenegger M, et al. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence. Oncotarget. 2016;7:3571-86. doi:10.18632/oncotarget.6527. PMID:26657295
   PubMed Web of Science ®Google Scholar
• Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-7. doi:10.1172/JCI9872. PMID:10772648
   PubMed Web of Science ®Google Scholar
• Nars MS, Kaneno R. Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int J Cancer. 2013;132:2471-8. doi:10.1002/ijc.27801. PMID:22927096
   PubMed Web of Science ®Google Scholar
• Kareva I, Waxman DJ, Lakka Klement G. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015;358:100-6. doi:10.1016/j.canlet.2014.12.039. PMID:25541061
   PubMed Web of Science ®Google Scholar
• Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017;18:946-57. doi:10.1016/S1470-2045(17)30355-8. PMID:28549783
   PubMed Web of Science ®Google Scholar
• Fleurence J, Cochonneau D, Fougeray S, Oliver L, Geraldo F, Terme M, Dorvillius M, Loussouarn D, Vallette F, Paris F, et al. Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside. Oncotarget. 2016;7:41172-85. doi:10.18632/oncotarget.9226. PMID:27172791
   PubMed Web of Science ®Google Scholar
• Huang R, Cheung NK, Vider J, Cheung IY, Gerald WL, Tickoo SK, Holland EC, Blasberg RG. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J. 2011;25:4138-49. doi:10.1096/fj.11-185033. PMID:21856782
   PubMed Web of Science ®Google Scholar
• Foley NH, Bray I, Watters KM, Das S, Bryan K, Bernas T, Prehn JH, Stallings RL. MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ. 2011;18:1089-98. doi:10.1038/cdd.2010.172. PMID:21212796
   PubMed Web of Science ®Google Scholar
• Fischer M, Berthold F. Characterization of the gene expression profile of neuroblastoma cell line IMR-5 using serial analysis of gene expression. Cancer Lett. 2003;190:79-87. doi:10.1016/S0304-3835(02)00581-5. PMID:12536080
   PubMed Web of Science ®Google Scholar
• Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986;89:271-7. doi:10.1016/0022-1759(86)90368-6. PMID:3486233
   PubMed Web of Science ®Google Scholar
• Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, et al. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res. 2003;9:3052-7. PMID:12912956
   PubMed Web of Science ®Google Scholar
• Ushmorov A, Debatin KM, Beltinger C. Growth inhibition of murine neuroblastoma cells by c-myc with cell cycle arrest in G2/M. Cancer Biol Ther. 2005;4:181-6. doi:10.4161/cbt.4.2.1439. PMID:15684616
   PubMed Web of Science ®Google Scholar
• Gilbert F, Balaban G, Moorhead P, Bianchi D, Schlesinger H. Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines. Cancer Genet Cytogenet. 1982;7:33-42. doi:10.1016/0165-4608(82)90105-4. PMID:7139592
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res. 1981;41:4678-86. PMID:6171342
   PubMed Web of Science ®Google Scholar
• Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, Vacca A, Ponzoni M. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. Int J Cancer. 2002;102:351-4. doi:10.1002/ijc.10742. PMID:12402304
   PubMed Web of Science ®Google Scholar